CISPLATIN, DOXORUBICIN, MITOMYCIN-C, AND 5-FLUOROURACIL FOR THE TREATMENT OF METASTATIC NONSMALL CELL LUNG-CANCER - LIMITED ACTIVITY OF AN AGGRESSIVE CHEMOTHERAPY REGIMEN
Jr. Murren et al., CISPLATIN, DOXORUBICIN, MITOMYCIN-C, AND 5-FLUOROURACIL FOR THE TREATMENT OF METASTATIC NONSMALL CELL LUNG-CANCER - LIMITED ACTIVITY OF AN AGGRESSIVE CHEMOTHERAPY REGIMEN, American journal of clinical oncology, 17(3), 1994, pp. 239-241
We conducted a Phase II study to determine the efficacy of cisplatin,
doxorubicin, mitomycin C, and 5-fluorouracil in patients with untreate
d non-small cell lung cancer. Patients were accrued through the Connec
ticut Oncology Association (COA), an organization composed of communit
y and university oncologists. Thirteen COA oncologists enrolled 30 pat
ients over 12 months and 26 were eligible for the final analysis. Pati
ents received cisplatin 75 mg/m2, doxorubicin 30 mg/m2, mitomycin C 6.
5 mg/m2, and 5-fluorouracil 750 mg/m2 on day 1. The treatment was repe
ated every 4 weeks, with mitomycin C given during the first 3 cycles a
nd then every other cycle. There were 5 (19%) partial responses, lasti
ng 1.3-7.3 months. The median time to progression was 10.3 months (0.3
-12.5 months). Median survival was 7.5 months (0.3-34 months). The maj
or toxicities were related to myelosuppression and there was one septi
c death. This study demonstrates the limited efficacy of an aggressive
regimen using ''active'' agents in patients with advanced non-small c
ell lung cancer.